News
ACCD
9.40
+0.53%
0.05
Accolade Q4 2024 Earnings Preview
Accolade (NASDAQ:ACCD) is scheduled to announce Q4 earnings results on Thursday, April 25th. The consensus EPS Estimate is $0.11 and the consensus revenue estimate is $123.92M. Over the last 2 years, ACCD has beaten revenue estimates 88% of the time.
Seeking Alpha · 1d ago
ACCOLADE INC <ACCD.O>: JEFFERIES CUTS TARGET PRICE TO $10 FROM $12
Reuters · 3d ago
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Susquehanna raised the price target for Occidental Petroleum Corporation from $70 to $81 on Friday. Chardan Capital increased Ocugen, Inc. Price target from $4 to $5. Keybanc boosted the price targets for Alphabet Inc. And ConocoPhillips.
Benzinga · 3d ago
Accolade Price Target Cut to $13.00/Share From $15.00 by Stifel
Dow Jones · 3d ago
Accolade Is Maintained at Buy by Stifel
Dow Jones · 3d ago
Stifel Maintains Buy on Accolade, Lowers Price Target to $13
Benzinga · 3d ago
ACCOLADE INC <ACCD.O>: STIFEL CUTS TARGET PRICE TO $13 FROM $15
Reuters · 3d ago
Weekly Report: what happened at ACCD last week (0415-0419)?
Weekly Report · 3d ago
Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Accolade (ACCD) and Intuitive Surgical (ISRG)
TipRanks · 3d ago
Accolade, Inc.: Statement of changes in beneficial ownership of securities
Press release · 5d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
TipRanks · 04/18 10:10
Weekly Report: what happened at ACCD last week (0408-0412)?
Weekly Report · 04/15 09:02
Accolade, Inc.: Report of proposed sale of securities
Press release · 04/11 20:05
Weekly Report: what happened at ACCD last week (0401-0405)?
Weekly Report · 04/08 09:02
Accolade: Staying Bullish On Favorable Developments
Accolade, Inc. (NASDAQ:ACCD) shares are rated as a Buy. Accolade will announce quarterly results for the third quarter of fiscal 2024 on April 25. The company's latest Artificial Intelligence Excellence Award provides a validation of the potential AI-related tailwinds for the company. I am positive on the company's new partner additions and its latest developments.
Seeking Alpha · 04/05 10:34
Weekly Report: what happened at ACCD last week (0325-0329)?
Weekly Report · 04/01 09:02
Following a 23% decline over last year, recent gains may please Accolade, Inc. (NASDAQ:ACCD) institutional owners
51% of the business is held by the top 7 shareholders of Accolade, Inc. (NASDAQ:ACCD). The company has 77% of its shares held by institutions. The institutional investors own more than half of the company. In the last 12 months, accolade has lost 23% and is now valued at US$57m. We take a look at the company's ownership of shares in a list of the most common types of shareholders.  Accolade owns US$17m worth of stock in the company .
Simply Wall St · 03/29 11:41
Weekly Report: what happened at ACCD last week (0318-0322)?
Weekly Report · 03/25 09:02
Strength Seen in Paymentus (PAY): Can Its 7.8% Jump Turn into More Strength?
NASDAQ · 03/21 12:11
Press Release: Accolade Promotes Kelsi McDonald Harris to Chief People Officer
Accolade Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President. McDonald Harris assumes new role on Executive Leadership Team to deliver an exceptional employee experience. She will oversee employee experience for Accolade's 2,400+ employees. She currently serves as Vice President of Strategy and Planning.
Dow Jones · 03/19 13:02
More
Webull provides a variety of real-time ACCD stock news. You can receive the latest news about Accolade, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ACCD
Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.